HTA in Fragile Settings

MarcusWelcome to the Access Brief — navigating the nexus of evidence, policy, and patient access in a complex global landscape. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always a pleasure to dive into these topics with you — today's focus on fragile settings feels particularly timely given the evolving global health challenges.

MarcusExactly. We're looking at HTA adaptation in conflict zones — why standard methodologies struggle where infrastructure collapses. Then social determinants of health in value assessments — how to measure non-clinical drivers. Plus blockchain for secure real-world evidence sharing, and Brexit's lingering effects on Northern Ireland's medicine access.

SaraThat first topic hits hard — the budget impact question in conflict zones is one where the field's conventional models completely unravel. How do you even model cost-effectiveness when health systems are actively under siege?

MarcusPrecisely. What strikes me is how we cling to QALY frameworks while clinics are bombed. The part that gives me pause is whether HTA bodies recognize this as a methodological crisis or just an implementation hurdle.

SaraI'd frame it slightly differently — it's not just about methodology, but about redefining 'value' when survival metrics replace quality-adjusted life years. The World Health Organization's recent field guidance on HTA in emergencies suggests this shift, but implementation remains theoretical.

MarcusThat connects to something I keep coming back to: the ethical imperative. If we can't generate evidence, do we default to compassionate access frameworks? And what precedent does that set for resource allocation elsewhere?

SaraRight, and from the payer side, the opportunity cost is staggering. Every dollar spent on emergency HTA is a dollar not spent on rebuilding primary care. But the alternative — no evidence at all — feels untenable.

MarcusExactly. Which brings us to social determinants. How are HTA bodies beginning to incorporate factors like housing instability or food insecurity into their assessments?

SaraThat's one where I see real momentum. NICE's recent pilot on 'social value weighting' in diabetes appraisals is fascinating, though I wonder if that's the full picture. The challenge is isolating attributable effects from systemic issues.

MarcusWhat's striking here is the methodological tension — can we truly quantify the impact of social determinants without conflating correlation and causation? The evidence base feels embryonic.

SaraAbsolutely. And payers would push back hard on premium pricing for therapies claiming social determinant mitigation without robust attribution studies. That's a line we can't cross.

MarcusWhich leads to blockchain for RWE security. How can distributed ledgers address the trust deficits in conflict-generated data?

SaraThis is one where technology might actually outpace ethics. The potential for tamper-proof evidence collection is clear, but who controls the nodes in contested territories? The governance framework feels entirely undeveloped.

MarcusThat's fair, though I think payers would see it differently — the primary appeal is auditability. If you can verify data provenance even when institutions collapse, that's transformative for decision-making.

SaraBut what about the digital divide? Implementing blockchain in regions with intermittent electricity feels like putting a Ferrari engine on a bicycle frame. The infrastructure gap undermines the whole premise.

MarcusAnd finally, Brexit's impact on Northern Ireland. How is the Windsor Framework actually playing out at the pharmacy level?

SaraThe practical reality is messy. We're seeing divergent formulary decisions between Northern Ireland and Great Britain that weren't anticipated. The supply chain frictions are creating de facto access disparities.

MarcusWhat strikes me is how this exposes the artificiality of regulatory boundaries. A medicine approved in London but not Belfast creates real patient harm. The EU-UK divergence on parallel imports compounds this.

SaraExactly. And from the payer perspective, the administrative burden of maintaining two separate pathways is unsustainable. The opportunity cost is diverted resources from actual patient care.

MarcusThat's the thread running through today — how geopolitical and humanitarian forces are forcing HTA to evolve beyond its comfort zone. The patient perspective demands we adapt.

SaraA lot to sit with. I'll be watching how HTA bodies respond to the social determinants pilot — whether it's a one-off or signals systemic change.

MarcusSame — and for me the unifying observation is that crisis exposes the brittleness of our frameworks. Worth questioning where we need flexibility versus坚守原则.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.